S'abonner

Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study - 22/09/22

Doi : 10.1016/S1473-3099(22)00345-0 
Martina E McMenamin, PhD a, Joshua Nealon, PhD a, , Yun Lin, MPH a, Jessica Y Wong, PhD a, Justin K Cheung, BSc a, Eric H Y Lau, PhD a, b, Peng Wu, PhD a, b, Gabriel M Leung, ProfMD a, b, Benjamin J Cowling, ProfPhD a, b,
a WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China 
b Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China 

*Correspondence to: Dr Joshua Nealon, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaWHO Collaborating Centre for Infectious Disease Epidemiology and ControlSchool of Public HealthLi Ka Shing Faculty of MedicineThe University of Hong KongHong Kong Special Administrative RegionChina**Prof Benjamin J Cowling, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaWHO Collaborating Centre for Infectious Disease Epidemiology and ControlSchool of Public HealthLi Ka Shing Faculty of MedicineThe University of Hong KongHong Kong Special Administrative RegionChina

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Background

Hong Kong maintained low circulation of SARS-CoV-2 until a major community epidemic of the omicron (B.1.1.529) sublineage BA.2 began in January, 2022. Both mRNA (BNT162b2 [Fosun Pharma-BioNTech]) and inactivated CoronaVac (Sinovac, Beijing, China) vaccines are widely available; however, vaccination coverage has been low, particularly in older adults aged 70 years or older. We aimed to assess vaccine effectiveness in this predominantly infection-naive population.

Methods

In this observational study, we used individual-level case data on mild or moderate, severe or fatal, and fatal disease in patients hospitalised with COVID-19 along with census information and coverage data of BNT162b2 and CoronaVac. We used a negative binomial model, adjusting for age, sex, and calendar day to estimate vaccine effectiveness of one, two, and three doses of both BNT162b2 and CoronaVac vaccines, and relative effectiveness by number of doses and vaccine type.

Findings

Between Dec 31, 2020, and March 16, 2022, 13·2 million vaccine doses were administered in Hong Kong’s 7·4-million population. We analysed data from confirmed cases with mild or moderate (n=5566), severe or fatal (n=8875), and fatal (n=6866) COVID-19. Two doses of either vaccine protected against severe disease and death within 28 days of a positive test, with higher effectiveness among adults aged 60 years or older with BNT162b2 (vaccine effectiveness 89·3% [95% CI 86·6–91·6]) compared with CoronaVac (69·9% [64·4–74·6]). Three doses of either vaccine offered very high levels of protection against severe or fatal outcomes (97·9% [97·3–98·4]).

Interpretation

Third doses of either BNT162b2 or CoronaVac provide substantial additional protection against severe COVID-19 and should be prioritised, particularly in older adults older than 60 years and others in high-risk populations who received CoronaVac primary schedules. Longer follow-up is needed to assess duration of protection across different vaccine platforms and schedules.

Funding

COVID-19 Vaccines Evaluation Program, Chinese Center for Disease Control and Prevention.

Le texte complet de cet article est disponible en PDF.

Plan


© 2022  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 22 - N° 10

P. 1435-1443 - octobre 2022 Retour au numéro
Article précédent Article précédent
  • Plagues and social change: the good, the bad, and the ugly
  • Vijay Shankar Balakrishnan
| Article suivant Article suivant
  • Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
  • Gary A Herman, Meagan P O’Brien, Eduardo Forleo-Neto, Neena Sarkar, Flonza Isa, Peijie Hou, Kuo-Chen Chan, Katharine J Bar, Ruanne V Barnabas, Dan H Barouch, Myron S Cohen, Christopher B Hurt, Dale R Burwen, Mary A Marovich, Bret J Musser, John D Davis, Kenneth C Turner, Adnan Mahmood, Andrea T Hooper, Jennifer D Hamilton, Janie Parrino, Danise Subramaniam, Alina Baum, Christos A Kyratsous, A Thomas DiCioccio, Neil Stahl, Ned Braunstein, George D Yancopoulos, David M Weinreich, COVID-19 Phase 3 Prevention Trial Team, Achint Chani, Adebiyi Adepoju, Adnan Mahmood, Aisha Mortagy, Ajla Dupljak, Alina Baum, Alison Brown, Amy Froment, Andrea Hooper, Andrea Margiotta, Andrew Bombardier, Anita Islam, Anne Smith, Arvinder Dhillon, Audra McMillian, Aurora Breazna, Ayesha Aslam, Barabara Carpentino, Bari Kowal, Barry Siliverstein, Benjamin Horel, Bo Zhu, Bret Musser, Brian Bush, Brian Head, Brian Snow, Bryan Zhu, Camille Debray, Careta Phillips, Carmella Simiele, Carol Lee, Carolyn Nienstedt, Caryn Trbovic, Casey (Kuo-Chen) Chan, Catherine Elliott, Chad Fish, Charlie Ni, Christa Polidori, Christine Enciso, Christopher Caira, Christopher Powell, Christos A. Kyratsous, Cliff Baum, Colin McDonald, Cynthia Leigh, Cynthia Pan, Dana Wolken, Danielle Manganello, David Liu, David Stein, David M. Weinreich, Dawlat Hassan, Daya Gulabani, Deborah Fix, Deborah Leonard, Deepshree Sarda, Denise Bonhomme, Denise Kennedy, Devin Darcy, Dhanalakshmi Barron, Diana Hughes, Diana Rofail, Dipinder Kaur, Divya Ramesh, Dona Bianco, Donna Cohen, Eduardo Forleo-Neto, Edward Jean-Baptiste, Ehsan Bukhari, Eileen Doyle, Elizabeth Bucknam, Emily Labriola-Tomkins, Emily Nanna, Esther Huffman O’Keefe, Evelyn Gasparino, Evonne Fung, Flonza Isa, Fung-Yee To, Gary Herman, George D. Yancopoulos, Georgia Bellingham, Giane Sumner, Grainne Moggan, Grainne Power, Haixia Zeng, Hazel Mariveles, Heath Gonzalez, Helen Kang, Hibo Noor, Ian Minns, Ingeborg Heirman, Izabella Peszek, James Donohue, Jamie Rusconi, Janice Austin, Janie Parrino, Jeannie Yo, Jenna McDonnell, Jennifer D. Hamilton, Jessica Boarder, Jianguo Wei, Jingchun Yu, Joanne Malia, Joanne Tucciarone, Jodie Tyler-Gale, John D. Davis, John Strein, Jonathan Cohen, Jonathan Meyer, Jordan Ursino, Joseph Im, Joseph Tramaglini, Joseph Wolken, Kaitlyn Potter, Kaitlyn Scacalossi, Kamala Naidu, Karen Browning, Karen Rutkowski, Karen Yau, Katherine Woloshin, Kelly Lewis-Amezcua, Kenneth Turner, Kimberly Dornheim, Kit Chiu, Kosalai Mohan, Kristina McGuire, Kristy Macci, Kurt Ringleben, Kusha Mohammadi, Kyle Foster, Latora Knighton, Leah Lipsich, Lindsay Darling, Lisa Boersma, Lisa Cowen, Lisa Hersh, Lisa Jackson, Lisa Purcell, Lisa Sherpinsky, Livia Lai, Lori Faria, Lori Geissler, Louise Boppert, Lyra Fiske, Marc Dickens, Marco Mancini, Maria C. Leigh, Meagan P. O’Brien, Michael Batchelder, Michael Klinger, Michael Partridge, Michel Tarabocchia, Michelle Wong, Mivianisse Rodriguez, Moetaz Albizem, Muriel O’Byrne, Ned Braunstein, Neena Sarkar, Neil Stahl, Nicole Deitz, Nicole Memblatt, Nirav Shah, Nitin Kumar, Olga Herrera, Oluchi Adedoyin, Ori Yellin, Pamela Snodgrass, Patrick Floody, Paul D’Ambrosio, Paul (Xiaobang) Gao, Peijie Hou, Philippa Hearld, Qin Li, Rachel Kitchenoff, Rakiyya Ali, Ramya Iyer, Ravikanth Chava, Rinol Alaj, Rita Pedraza, Robert Hamlin, Romana Hosain, Ruchin Gorawala, Ryan White, Ryan Yu, Rylee Fogarty, S. Balachandra Dass, Sagarika Bollini, Samit Ganguly, Sandra DeCicco, Sanket Patel, Sarah Cassimaty, Selin Somersan-Karakaya, Shane McCarthy, Sharon Henkel, Shazia Ali, Shelley Geila Shapiro, Somang Kim, Soraya Nossoughi, Stephanie Bisulco, Steven Elkin, Steven Long, Sumathi Sivapalasingam, Susan Irvin, Susan Wilt, Tami Min, Tatiana Constant, Theresa Devins, Thomas DiCioccio, Thomas Norton, Travis Bernardo, Tzu-Chien Chuang, Victor (Jianguo) Wei, Vinh Nuce, Vishnu Battini, Wilson Caldwell, Xiaobang Gao, Xin Chen, Yanmei Tian, Yasmin Khan, Yuming Zhao, Yunji Kim, Bonnie Dye, Christopher B. Hurt, Dale R. Burwen, Dan H. Barouch, David Burns, Elizabeth Brown, Katharine J. Bar, Mary Marovich, Meredith Clement, Myron S. Cohen, Nirupama Sista, Ruanne V. Barnabas, Sheryl Zwerski

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.